array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2519) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(80) "Sanofi, ‘Dupixent’ CSU phase 3 “successful”…approval “reattempted”" ["snippet_en"]=> string(39) "Reporter Shin Chang-min of Biospectator" ["url"]=> string(61) "http://www.biospectator.com/view/news_view.php?varAtcId=23063" ["image_url"]=> string(78) "https://images.businessradar.com/articles/5d842f69-20cb-473e-b228-2678a26b91bf" ["source"]=> string(16) "biospectator.com" ["publication_date"]=> string(10) "2024-09-21" ["categories"]=> array(0) { } } [1]=> array(7) { ["title_en"]=> string(151) "Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old, by @GlobeNewswire" ["snippet_en"]=> string(117) "Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old" ["url"]=> string(86) "https://ceo.ca/@GlobeNewswire/press-release-dupixent-recommended-for-eu-approval-46bec" ["image_url"]=> string(78) "https://images.businessradar.com/articles/fd56ebd9-43db-42bb-9d7d-0441585f4723" ["source"]=> string(6) "ceo.ca" ["publication_date"]=> string(10) "2024-09-20" ["categories"]=> array(2) { [0]=> string(13) "Collaboration" [1]=> string(8) "Epidemic" } } [2]=> array(7) { ["title_en"]=> string(52) "Urticaria: Next indication for blockbuster Dupixent?" ["snippet_en"]=> string(200) "Hives, angioedema and itching are the main symptoms of chronic spontaneous urticaria, or CSU for short. Sanofi has now presented the results of the confirmatory phase 3 study of Dupixent (dupilumab)." ["url"]=> string(120) "https://www.apotheke-adhoc.de/rubriken/detail/dermopharmazie/urtikaria-naechste-indikation-fuer-kassenschlager-dupixent/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/97a4e991-b20b-4b1b-b080-d5b296a5bdc0" ["source"]=> string(17) "apotheke-adhoc.de" ["publication_date"]=> string(10) "2024-09-19" ["categories"]=> array(1) { [0]=> string(13) "Collaboration" } } [3]=> array(7) { ["title_en"]=> string(74) "Regeneron holds panel and networking dinner for students with disabilities" ["snippet_en"]=> string(202) "Regeneron, a biotechnology company, teamed up with Binghamton University’s Neurodiversity Club this week to host a panel spotlighting the company’s ASPIRE-DI program, which promotes accessibility..." ["url"]=> string(115) "https://www.bupipedream.com/news/regeneron-holds-panel-and-networking-dinner-for-students-with-disabilities/156203/" ["image_url"]=> NULL ["source"]=> string(15) "bupipedream.com" ["publication_date"]=> string(10) "2024-09-19" ["categories"]=> array(0) { } } [4]=> array(7) { ["title_en"]=> string(47) "REGN: 3 Genomics Stocks Transforming Healthcare" ["snippet_en"]=> string(291) "Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN): Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As this field rapidly evolves, investing in fundamentally sound genomics stocks like Regeneron Pharmaceuticals( REGN), Alnylam" ["url"]=> string(84) "https://stocknews.com/news/regn-alny-ilmn-3-genomics-stocks-transforming-healthcare/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3bc6d1f2-8a6d-4ce5-8b05-33e3fc6c1dcc" ["source"]=> string(13) "stocknews.com" ["publication_date"]=> string(10) "2024-09-19" ["categories"]=> array(0) { } } [5]=> array(7) { ["title_en"]=> string(108) "News: Clinical Update: CRISPR Therapy for Transthyretin Amyloidosis Results in Rapid and Prolonged Responses" ["snippet_en"]=> string(293) "In this week's update, we provide news about Intellia Therapeutics' and Regeneron's ongoing Phase 1 trial for NTLA-2001 in transthyretin amyloidosis. Updated clinical data demonstrates that the experimental in vivo CRISPR therapy resulted in rapid, deep and sustained responses in 15 patients." ["url"]=> string(136) "https://crisprmedicinenews.com/news/clinical-update-crispr-therapy-for-transthyretin-amyloidosis-results-in-rapid-and-prolonged-respons/" ["image_url"]=> NULL ["source"]=> string(22) "crisprmedicinenews.com" ["publication_date"]=> string(10) "2024-09-19" ["categories"]=> array(0) { } } [6]=> array(7) { ["title_en"]=> string(79) "Students from Erbaa will represent Turkey in the Project Competition in America" ["snippet_en"]=> string(158) "High school students in Erbaa achieved great success by coming 3rd in Türkiye in the research projects competition held in the Technological Design category." ["url"]=> string(101) "https://www.kelkitgazetesi.com/erbaali-ogrencilerin-basarisi-amerikada-proje-yarismasina-katilacaklar" ["image_url"]=> NULL ["source"]=> string(18) "kelkitgazetesi.com" ["publication_date"]=> string(10) "2024-09-18" ["categories"]=> array(0) { } } [7]=> array(7) { ["title_en"]=> string(97) "Leadership Insights from Regeneron’s Christine Enciso: Priorities, Projects and Personal Growth" ["snippet_en"]=> string(140) "Gain clinical trial leadership insights from Christine Enciso, Vice President of Development Services and Operational Excellence, Regeneron." ["url"]=> string(117) "https://xtalks.com/leadership-insights-from-regenerons-christine-enciso-priorities-projects-and-personal-growth-3808/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1d83f1be-00f4-40d6-89c1-8edcfb2ffdda" ["source"]=> string(10) "xtalks.com" ["publication_date"]=> string(10) "2024-09-18" ["categories"]=> array(0) { } } [8]=> array(7) { ["title_en"]=> string(59) "Defensive stocks in an environment of slowing global growth" ["snippet_en"]=> string(87) "As global growth continues to slow, UBS advises investors to focus on defensive stocks." ["url"]=> string(95) "https://burzovnisvet.cz/2024/09/defenzivni-akcie-v-prostredi-zpomalujiciho-se-globalniho-rustu/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/134ee4a4-f0fb-48d2-9051-69f0bc66f2db" ["source"]=> string(15) "burzovnisvet.cz" ["publication_date"]=> string(10) "2024-09-18" ["categories"]=> array(1) { [0]=> string(12) "Stock Market" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(219) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(195) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(163) } [3]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(111) } [4]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(109) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(104) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(90) } [7]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(65) } [8]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(54) } [9]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(52) } [10]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(52) } [11]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(49) } [12]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(48) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(41) } [14]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(39) } [15]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(36) } [16]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(35) } [17]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(34) } [18]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(32) } [19]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(31) } [20]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(31) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(31) } [22]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(30) } [23]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(29) } [24]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [25]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(27) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(23) } [28]=> array(2) { ["name"]=> string(8) "Politics" ["count"]=> int(19) } [29]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(19) } } } c469a-us-regeneron-pharmaceuticals-inc